In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2606-2612

  Allen, George P ^a   Cha, Raymond ^a   Rybak, Michael J ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; GLYCOPEPTIDE; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG EFFECT; HALF LIFE TIME; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; STAPHYLOCOCCUS;

ANTIBIOTICS; ANTIBIOTICS, COMBINED; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; ENTEROCOCCUS; HALF-LIFE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS; SUPPORT, NON-U.S. GOV'T; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION;

EID: 0035991980     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2606-2612.2002     Document Type: Article

References (34)

1. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristindalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations
2. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model
3. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid
4. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives
5. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
6. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
7. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993
8. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms
9. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program
10. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
11. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500
12. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
13. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections
14. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model
15. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus
16. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
17. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus
18. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis
19. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
20. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents
21. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin-dalfopristin)
22. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
23. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains
24. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
25. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
26. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci. Enterococcus faecalis, and Enterococcus faecium
27. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates
28. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin
29. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections
30. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients
31. Quinupristin-dalfopristin combined with β-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics
32. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics